Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Endothelin A receptor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    80 result(s) found for: Endothelin A receptor. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2005-001193-28 Sponsor Protocol Number: AMB-320/321-E Start Date*: 2005-11-08
    Sponsor Name:Myogen, Inc
    Full Title: ARIES-320/321-E “A Long-Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 or AMB-321"
    Medical condition: Pulmonary Arterial Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000812-29 Sponsor Protocol Number: AMB 320 Start Date*: 2005-09-21
    Sponsor Name:Myogen, Inc.
    Full Title: Ambrisentan in PAH - A Phase III, Randomised, Double- Blind, Placebo- Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects with Pulmonary Arterial Hypertension
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    7.0 10037400 low
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) AT (Completed) BE (Completed) IT (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003140-27 Sponsor Protocol Number: V1.0/OPHT-020606 Start Date*: 2006-07-25
    Sponsor Name:Department of Clinical Pharmacology
    Full Title: Effects of non-specific Endothelin-A receptor blockade on ocular blood flow in patients with glaucoma
    Medical condition: patients with primary open angle glaucoma in comparision to a healthy control group.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000701-61 Sponsor Protocol Number: BIRD-1 250705 Start Date*: 2005-11-29
    Sponsor Name:University College London
    Full Title: An open label trial of the dual specificity endothelin receptor antagonist bosentan in established scleroderma renal crisis
    Medical condition: Scleroderma renal crisis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-005679-33 Sponsor Protocol Number: KKSH-042 Start Date*: 2011-01-20
    Sponsor Name:Medizinische Fakultät der Martin-Luther-Universität Halle-Wittenberg
    Full Title: Influence of the selective endothelin receptor-blocker Ambrisetan on the portal pressure in patients with cirrhosis
    Medical condition: Portal hypertension and hepatic cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10019805 - Hepatobiliary disorders 10036200 Portal hypertension PT
    16.1 10019805 - Hepatobiliary disorders 10009213 Cirrhosis of liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-003482-68 Sponsor Protocol Number: BAY 63-2521/12934 Start Date*: 2008-11-26
    Sponsor Name:Bayer HealthCare AG
    Full Title: Randomized, double-blind, placebo-controlled, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with symptom...
    Medical condition: Pulmonary Arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064911 Pulmonary arterial hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Prematurely Ended) AT (Completed) ES (Completed) NL (Completed) FR (Completed) SE (Completed) GB (Completed) CZ (Completed) DK (Completed) BE (Completed) IT (Completed) PT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2008-004533-21 Sponsor Protocol Number: 03602 Start Date*: 2010-06-25
    Sponsor Name:ICIN
    Full Title: The role of Bosentan in fontan patients: improvement of aerobic capacity
    Medical condition: To study whether bosentan (endothelin receptor inhibitor) improves aerobic capacity (VO2max) and exercise performance in adult patients with a Fontan operation.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064911 Pulmonary arterial hypertension LLT
    Population Age: Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004391-36 Sponsor Protocol Number: AC-052-402 Start Date*: 2005-05-23
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: A multicenter, open-label, single-arm safety study to investigate the effects of chronic TRACLEER® treatment on testicular function in male patients with pulmonary arterial hypertension
    Medical condition: Many endothelin receptor antagonists have profound effects on the histology and function of the testes in animals. These drugs have been shown to induce atrophy of the seminiferous tubules of the t...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2004-002686-21 Sponsor Protocol Number: Bosentan1 Start Date*: 2005-02-22
    Sponsor Name:Dept of Dermatology
    Full Title: Efficacy of Endothelin 1 receptor antagonist Bosentan in secondary Raynauds Syndrom
    Medical condition: secondary Raynauds Syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002358-38 Sponsor Protocol Number: RET-D-001 Start Date*: 2015-04-28
    Sponsor Name:Travere Therapeutics, Inc.
    Full Title: PROTOCOL RET-D-001: EFFICACY AND SAFETY OF SPARSENTAN (RE-021), A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, IN PATIENTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): A RANDOMIZED...
    Medical condition: FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10067757 Focal segmental glomerulosclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001412-38 Sponsor Protocol Number: CQCC374X2201 Start Date*: 2017-07-27
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, parallel-group, placebo-controlled subject and investigator blinded study to assess the safety, tolerability, pharmacokinetics and efficacy of QCC374 in the treatment of pulmonary art...
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002623-42 Sponsor Protocol Number: 66623 Start Date*: 2019-02-18
    Sponsor Name:Academic Medical Center
    Full Title: Vasospastic angina treatment by Endothelin Receptor Antagonism; a proof of concept study
    Medical condition: Vasospastic angina, i.e. epicardial vasospasm or microvascular coronary dysfunction.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10002383 Angina pectoris PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005462-34 Sponsor Protocol Number: 202006RCT Start Date*: 2021-06-23
    Sponsor Name:Thoraxklinik Heidelberg gGmbH
    Full Title: An open-label, prospective, single centre study of the effects of Riociguat on RIght VEntricular size and function in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
    Medical condition: Symptomatic pulmonary arterial hypertension with a mean pulmonary artery pressure >20 mmHg and pulmonary vascular resistance ≥2 Wood Units, pulmonary arterial wedge pressure ≤15 mmHg (Group I / Nic...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-002686-30 Sponsor Protocol Number: CEP-AZ-SH-02 Start Date*: 2009-04-15
    Sponsor Name:Christie Hospital NHS Foundation Trust
    Full Title: Assessment of the effects of the specific endothelin-A antagonist ZD4054 on prostate cancer biomarkers in patients with castrate-resistant metastatic disease
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036909 Prostate cancer metastatic LLT
    Population Age: Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-003495-53 Sponsor Protocol Number: NL59009.018.16 Start Date*: 2016-11-29
    Sponsor Name:Academic Medical Center - Cardiology
    Full Title: Prostacyclin receptor agonist Selexipag in patients with pulmonary arterial hypertension and congenital heart disease
    Medical condition: Pulmonary arterial hypertension related to congenital heart disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001067-36 Sponsor Protocol Number: 18588 Start Date*: 2016-11-21
    Sponsor Name:Bayer AG
    Full Title: A prospective, randomized, international, multicenter, double-arm, controlled, open-label study of Riociguat in patients with pulmonary arterial hypertension (PAH) who are on a stable dose of phosp...
    Medical condition: Pulmonary Arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) PT (Completed) AT (Completed) CZ (Completed) GB (Completed) DE (Completed) BE (Completed) NL (Completed) DK (Completed) GR (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012450-20 Sponsor Protocol Number: AC-051-206 Start Date*: 2009-10-15
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: Multicenter, open-label, non-comparative, proof-of-concept, phase 2a study to evaluate the effect of a single infusion of tezosentan on pulmonary vascular resistance in patients with stable, chroni...
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    12.0 10064911 Pulmonary arterial hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-001139-22 Sponsor Protocol Number: POPH Start Date*: 2011-06-29
    Sponsor Name:Medizinische Universität Graz, Klin. Abteilung für Gastroenterologie und Hepatologie
    Full Title: AMBRISENTAN FOR TREATMENT OF PORTOPULMONARY HYPERTENSION (POPH): A PILOT STUDY
    Medical condition: Portopulmonary Hypertension (PoPH) and Hepatopulmonary Syndrome HPS are present in a considerable number of patients with compensated cirrhosis. Treatment of PoPH with ambrisentan is well tolerated...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10067281 Portopulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005361-19 Sponsor Protocol Number: 123-2006 Start Date*: 2007-03-09
    Sponsor Name:St Georges Hospital
    Full Title: Evaluation of the efficacy of the dual endothelin 1 receptor antagonist Bosentan in the treatment of Pulmonary Hypertension secondary to Chronic Obstructive Pulmonary Disease and in the treatment o...
    Medical condition: Pulmonary Hypertension secondary to Chronic Obstructive Pulmonary Disease and secondary to Sarcoid Patients devolop pulmonary hypertension for various reasons, two common causes are Chronic Obstru...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10037400 Pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-000604-14 Sponsor Protocol Number: SPP301CRD15 Start Date*: 2005-08-24
    Sponsor Name:Speedel Pharma Ltd.
    Full Title: A randomised, double blind, placebo controlled, parallel group study to assess the effect of the endothelin receptor antagonist avosentan on time to doubling of serum creatinine, end stage renal di...
    Medical condition: Diabetic Nephropathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FI (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) LT (Prematurely Ended) SE (Prematurely Ended) SK (Completed) DE (Prematurely Ended) EE (Prematurely Ended) IT (Prematurely Ended) ES (Ongoing) LV (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 22:21:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA